Tandem Diabetes Care Inc
$ 21.55
-1.96%
02 Jan - close price
- Market Cap 1,490,296,000 USD
- Current Price $ 21.55
- High / Low $ 22.45 / 21.55
- Stock P/E N/A
- Book Value 1.96
- EPS -3.03
- Next Earning Report 2026-02-25
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.06 %
- ROE -1.10 %
- 52 Week High 38.28
- 52 Week Low 9.98
About
Tandem Diabetes Care, Inc. is a prominent medical device manufacturer located in San Diego, California, specializing in cutting-edge insulin delivery technologies for individuals with insulin-dependent diabetes. The company's flagship t:slim X2 insulin delivery system integrates state-of-the-art features such as automated insulin delivery and continuous glucose monitoring, establishing Tandem as a leader in the diabetes management sector. With a strong commitment to innovation and a robust research and development framework, Tandem is well-positioned to capitalize on the growing demand for personalized and intelligent healthcare solutions, aiming to enhance patient outcomes in an evolving market.
Analyst Target Price
$24.81
Quarterly Earnings
| Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | Dec 2022 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2025-11-06 | 2025-08-06 | 2025-04-30 | 2025-02-19 | 2024-11-06 | 2024-08-01 | 2024-05-02 | 2024-02-21 | 2023-11-01 | 2023-08-03 | 2023-05-03 | 2023-02-22 |
| Reported EPS | -0.31 | -0.78 | -0.6652 | -0.4356 | -0.35 | -0.48 | -0.63 | -0.27 | -0.38 | -0.55 | -1.92 | -0.25 |
| Estimated EPS | -0.32 | -0.4 | -0.6077 | -0.2357 | -0.4 | -0.54 | -0.76 | -0.25 | -0.34 | -0.53 | -0.52 | -0.06 |
| Surprise | 0.01 | -0.38 | -0.0575 | -0.1999 | 0.05 | 0.06 | 0.13 | -0.02 | -0.04 | -0.02 | -1.4 | -0.19 |
| Surprise Percentage | 3.125% | -95% | -9.4619% | -84.8112% | 12.5% | 11.1111% | 17.1053% | -8% | -11.7647% | -3.7736% | -269.2308% | -316.6667% |
Next Quarterly Earnings
| Dec 2025 | |
|---|---|
| Reported Date | 2026-02-25 |
| Fiscal Date Ending | 2025-12-31 |
| Estimated EPS | -0.06 |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: TNDM
2025-12-31 13:07:00
This article highlights five biotech companies, Avant Technologies, Novo Nordisk, Eledon Pharmaceuticals, Viking Therapeutics, and Tandem Diabetes Care, that are pioneering new treatments for diabetes, moving beyond traditional insulin shots. These companies are focusing on functional cures, regenerative medicine, and advanced drug delivery systems. The innovations aim to reduce insulin dependence, improve patient quality of life, and address the growing global diabetes market.
2025-12-31 06:09:05
The Global Disposable Insulin Pumps Market is projected to grow from US$ 3.83 billion in 2024 to US$ 6.9 billion by 2032, exhibiting a CAGR of 7.76%. This growth is driven by recent innovations and increasing adoption of tubeless patch pumps for diabetes management in regions like the US and Europe. Key players in this market include Medtronic, Insulet Corporation, and Roche.
2025-12-30 22:09:05
Tandem Diabetes Care's board updated its bylaws on December 26, 2025, to strengthen governance rules, particularly concerning shareholder nomination procedures and proxy processes. These changes aim to streamline corporate governance, formalize the board's control over shareholder meetings, and align with Delaware corporate law. The move may influence future interactions with activist investors and other shareholders.
2025-12-29 18:09:22
Multiple insiders at Tandem Diabetes Care (NASDAQ:TNDM) have recently purchased stock, sending a positive signal to shareholders. While these purchases were made at prices below the current market value, they suggest insiders see value in the company and are aligning their interests with other shareholders. The Executive VP & COO, Jean-Claude Kyrillos, made the largest recent purchase of US$191k worth of shares at US$18.12 each.
2025-12-25 23:09:00
Rosen Law Firm is investigating potential securities claims against Tandem Diabetes Care, Inc. (NASDAQ: TNDM) following allegations that the company issued materially misleading business information. This investigation comes after Tandem Diabetes announced a voluntary medical device correction for select t:slim X2 insulin pumps due to a speaker-related issue that can halt insulin delivery, causing a 19.9% stock drop. The firm encourages investors who purchased Tandem Diabetes securities to join a prospective class action to recover losses.
2025-12-23 20:09:55
The Rosen Law Firm is investigating potential securities claims against Tandem Diabetes Care, Inc. (NASDAQ: TNDM) following a voluntary medical device correction for select t:slim X2 insulin pumps, which caused the company's stock to fall by 19.9%. Investors who purchased Tandem Diabetes securities are encouraged to contact the firm to inquire about joining a prospective class action to recover losses. The firm highlights its track record in securities class actions and shareholder derivative litigation.
